Collaboration Agreement - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	May 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments receivable	$ 135,000
Deferred Revenue		$ 8,300		$ 8,300
Deferred Revenue Related to Development Activities		2,700		2,700
Collaboration revenue		407		5,774
Clinical Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received	$ 12,000
Upfront payment recognition in future periods to settlement of obligation		12,000		$ 12,000
Deferred revenue, description				Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations. The potential milestone payments that the Company is eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement.
Performance Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue		400	$ 0
Milestone Achievements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue		$ 0	$ 0